Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study
The Journal of Clinical Endocrinology & Metabolism · 28.07.2026
DOI: 10.1210/clinem/dgag302 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.07.2026. Verfasst von Abdulrahman Ghaleb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Hypercalcemia in sarcoidosis is classically attributed to granuloma-mediated calcitriol excess, but primary hyperparathyroidism (PHPT)—the most common cause of ambulatory hypercalcemia—frequently coexists. These 2 etiologies are mechanistically distinct: sarcoid hypercalcemia is suppressed-PTH and 1,25(OH)2D-driven, while PHPT is autonomous-PTH-driven and surgically curable. Because both can independently sustain hypercalcemia, attribution to sarcoidosis alone risks anchoring bias and delayed identification of PHPT.
Objective
To determine PHPT prevalence in sarcoidosis, characterize hypercalcemia-evaluation adequacy, and assess parathyroidectomy (PTX) impact on all-cause mortality.
Design
Retrospective cohort study.
Setting
TriNetX US Collaborative Network, federated electronic health record data from >120 million patients. Patients 117 395 adults with ICD-10 sarcoidosis (D86) and ≥1 serum calcium measurement.
Interventions
None (observational). Main outcome measures Intact parathyroid hormone (iPTH) assessment rate; biochemical and coded PHPT prevalence; PTX utilization and outcomes; all-cause mortality.
Results
Hypercalcemia: 31.3% (n = 36 790); only 30.5% received iPTH. Biochemical PHPT: 3.0% (n = 3493)—of whom 75.4% (n = 2633) had no ICD-10 code. PTX in coded PHPT: 36.6% (n = 315), with 74.6% biochemical cure. Hypercalcemia hazard ratio (HR) 1.33 (1.29-1.38), coded PHPT HR 1.50 (1.40-1.60), no-PTX HR 4.2 (2.7-6.4); all P < .001.
Conclusion
PHPT is prevalent, profoundly under-evaluated, and under-treated in sarcoidosis. Routine iPTH measurement and timely surgical referral are essential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
- University of California, Riverside, Riverside, California, USA.
- Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA.
- Department of Surgery, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
ORCID-Profile: Abdulrahman Ghaleb, Yaser Bashumeel
Zitieren
APA
Ghaleb, A., Abdelmaksoud, A., Bashumeel, Y., Abdalnaeem, M., Alselek, A., Noureldine, S. I., & Kandil, E. (2026). Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag302
Vancouver
Ghaleb A, Abdelmaksoud A, Bashumeel Y, Abdalnaeem M, Alselek A, Noureldine SI, et al. Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag302
BibTeX
@article{Ghaleb2026,
author = {Ghaleb, Abdulrahman and Abdelmaksoud, Ahmed and Bashumeel, Yaser and Abdalnaeem, Mahmoud and Alselek, Anas and Noureldine, Salem I and Kandil, Emad},
title = {Prevalence and outcomes of primary hyperparathyroidism in sarcoidosis patients: a large-scale retrospective cohort study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgag302}
}
EUVIMED